

Publikationsliste

Karin Holmskov Hansen

Speciallæge i Klinisk Onkologi

[1]

Stensland EM, Stensgaard S, Eide IJZ, Nilssen Y, Horndalsveen H, Cicenias S, ..., **Karin Holmskov Hansen et al. Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial** (the FIOL study). Lung Cancer 2026;214:109338.
<https://doi.org/10.1016/j.lungcan.2026.109338>.

[2]

Ulhøi MP, Andersen ER, Maansson CT, Larsen LM, Stelmach M, Andersen JL, **Karin Holmskov Hansen et al. Clinical and molecular characteristics of 42 Danish patients with metastatic ALK fusion-positive lung cancer treated with first-line alectinib: A nationwide study**. Cancer Treatment and Research Communications 2025;45:100993.
<https://doi.org/10.1016/j.ctarc.2025.100993>.

[3]

Friis RB, Pappot H, Hjollund NH, McCulloch T, Holt MI, Persson GF, ... **Karin Holmskov Hansen et al. Remote Symptom Monitoring of Patients With Advanced Lung Cancer** (The ProWide Study): A Randomized Controlled Trial. JCO Oncol Pract 2025;21:813–23.
<https://doi.org/10.1200/OP-24-00562>.

[4]

Ahn M-J, Delmonte A, Ghosh S, Yang T-Y, Yang JC-H, Han J-Y, **Karin Holmskov Hansen et al. Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial**. Future Oncology 2025;21:3935–45.
<https://doi.org/10.1080/14796694.2025.2592527>.

[5]

Waterhouse DM, Rothschild S, Dooks C, Menecier B, Bozorgmehr F, Majem M, ... **Karin Holmskov Hansen et al. Patient-reported outcomes in CodeBreak 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation**. Lung Cancer 2024;196:107921. <https://doi.org/10.1016/j.lungcan.2024.107921>.

[6]

Hansen KH, Lyng MB, Kodahl AR, Asmussen JT, Arshad A, Petersen H, et al. Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options (PRECODE): study protocol of a prospective, non-randomized, cohort study. BMC Medical Genomics 2024;17:274.
<https://doi.org/10.1186/s12920-024-02033-z>.

[7]

Andersen JL, Johansen JS, Urbanska EM, Meldgaard P, Hjorth-Hansen P, Kristiansen C, ...Karin Holmskov Hansen. Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis. Lung Cancer Management 2024;13:LMT68. <https://doi.org/10.2217/lmt-2023-0013>.

[8]

Kringelbach T, Højgaard M, Rohrberg K, Spanggaard I, Laursen BE, Ladekarl M,... Karin Holmskov Hansen et al. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. BMC Cancer 2023;23:182.
<https://doi.org/10.1186/s12885-023-10632-9>.

[9]

Hansen KH, Johansen JS, Urbanska EM, Meldgaard P, Hjorth-Hansen P, Kristiansen C, et al. Clinical outcomes of ALK + non-small cell lung cancer in Denmark. Acta Oncologica 2023;62:1775–83. <https://doi.org/10.1080/0284186X.2023.2263153>.

[10]

Bjørnhart B, Mouritzen MT, Kristiansen C, Schytte T, Wedervang K, Pøhl M and Karin Holmskov Hansen. 5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy. Acta Oncologica 2023;62:861–70. <https://doi.org/10.1080/0284186X.2023.2238544>.

[11]

Bjørnhart B, Kristiansen C, Asmussen J, Hansen KH, Wedervang K, Jørgensen TL, et al. Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy. Thrombosis Research 2023;221:164–72.
<https://doi.org/10.1016/j.thromres.2022.10.020>.

[12]

Mouritzen MT, Junker KF, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, ... **Karin Holmskov Hansen et al. Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.** Acta Oncologica 2022;61:409–16. <https://doi.org/10.1080/0284186X.2021.2023213>.

[13]

Held MK, Hansen O, Schytte T, **Hansen KH**, Bahij R, Nielsen M, et al. **Outcomes of prophylactic cranial irradiation in patients with small cell lung cancer in the modern era of baseline magnetic resonance imaging of the brain.** Acta Oncologica 2022;61:185–92. <https://doi.org/10.1080/0284186X.2021.1974553>.

[14]

Gettinger SN, Huber RM, Kim D-W, Bazhenova L, **Hansen KH**, Tiseo M, et al. **Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.** JTO Clin Res Rep 2022;3:100385. <https://doi.org/10.1016/j.jtocrr.2022.100385>.

[15]

Eide IJZ, Stensgaard S, Helland Å, Ekman S, Mellemgaard A, **Hansen KH**, et al. **Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials.** Transl Lung Cancer Res 2022;11:953–63. <https://doi.org/10.21037/tlcr-21-995>.

[16]

Bjørnhart B, **Hansen KH**, Asmussen JT, Jørgensen TL, Herrstedt J, Schytte T. **Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis.** Cancers 2022;14:1682. <https://doi.org/10.3390/cancers14071682>.

[17]

Pfeiffer P, Qvortrup C, **Hansen KH**. **How to select cancer patients for immunotherapy.** EBioMedicine 2021;63:103184. <https://doi.org/10.1016/j.ebiom.2020.103184>.

[18]

Mouritzen MT, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, Livbjerg A, ... **Karin H Hansen et al. Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy.** Cancers 2021;13:4846. <https://doi.org/10.3390/cancers13194846>.

[19]

Eide IJZ, Grut H, Helland Å, Ekman S, Sørensen JB, **Hansen KH**, et al. **Intracranial effect of osimertinib in relapsed *EGFR*-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study.** Acta Oncologica 2021;60:1565–71. <https://doi.org/10.1080/0284186X.2021.1973092>.

[20]

Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N,... **Karin Hansen** et al. **Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.** Journal of Thoracic Oncology 2021;16:1547–58. <https://doi.org/10.1016/j.jtho.2021.02.009>.

[21]

Bjørnhart B, **Hansen KH**, Jørgensen TL, Herrstedt J, Schytte T. **Incidence, risk factors and clinical outcome of venous thromboembolism in non-small cell lung cancer patients receiving immune checkpoint inhibition.** Thrombosis Update 2021;4:100056. <https://doi.org/10.1016/j.tru.2021.100056>.

[22]

Huber RM, **Hansen KH**, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, et al. **Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.** Journal of Thoracic Oncology 2020;15:404–15. <https://doi.org/10.1016/j.jtho.2019.11.004>.

[23]

Eide IJZ, Helland Å, Ekman S, Mellemgaard A, **Hansen KH**, Ciconas S, et al. **Osimertinib in T790M-positive and -negative patients with *EGFR*-mutated advanced non-small cell lung cancer (the TREM-study).** Lung Cancer 2020;143:27–35. <https://doi.org/10.1016/j.lungcan.2020.03.009>.

[24]

Ebert EBF, McCulloch T, **Hansen KH**, Linnet H, Sørensen B, Meldgaard P. **Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.** Lung Cancer 2020;141:37–43. <https://doi.org/10.1016/j.lungcan.2019.12.016>.

[25]

Christensen NL, Rasmussen TR, **Hansen KH**, Christensen J, Dalton SO. **Comorbidity and early death in Danish stage I lung cancer patients – an individualised approach.** Acta Oncologica 2020;59:994–1001. <https://doi.org/10.1080/0284186X.2020.1764096>.

[26]

Boysen Fynboe Ebert E, McCulloch T, **Holmskov Hansen K**, Linnet H, Sorensen B, Meldgaard P. **Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.** Lung Cancer 2020;143:67–72. <https://doi.org/10.1016/j.lungcan.2020.03.020>.

[27]

Bjørnhart B, **Hansen KH**, Jørgensen TL, Herrstedt J, Schytte T. **Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study.** Acta Oncologica 2019;58:953–61. <https://doi.org/10.1080/0284186X.2019.1615636>.

[28]

Bahij R, Jeppesen SS, Olsen KE, Halekoh U, **Holmskov K**, Hansen O. **Outcome of treatment in patients with small cell lung cancer in poor performance status.** Acta Oncol 2019;58:1612–7. <https://doi.org/10.1080/0284186X.2019.1637934>.

[29]

Herrstedt J, Summers Y, Daugaard G, Christensen TB, **Holmskov K**, Taylor PD, et al. **Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study.** Support Care Cancer 2018;26:139–45. <https://doi.org/10.1007/s00520-017-3825-2>.

[30]

Kim D-W, Tiseo M, Ahn M-J, Reckamp KL, **Hansen KH**, Kim S-W, et al. **Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.** JCO 2017;35:2490–8. <https://doi.org/10.1200/JCO.2016.71.5904>.

[31]

Kristiansen C, Schytte T, **Hansen KH**, Holtved E, Hansen O, On behalf of the Academy of Geriatric Cancer Research (AgeCare). **Trends in lung cancer in elderly in Denmark, 1980–2012.** Acta Oncologica 2016;55:46–51. <https://doi.org/10.3109/0284186X.2015.1114676>.

[32]

Kristiansen C, Olsen KE, Hansen NC, **Hansen KH**, Hansen O. **Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.** Acta Oncologica 2012;51:948–9. <https://doi.org/10.3109/0284186X.2011.652739>.

[33]

Hansen O, Sørensen P, **Hansen KH**. **The occurrence of hyponatremia in SCLC and the influence on prognosis.** Lung Cancer 2010;68:111–4.
<https://doi.org/10.1016/j.lungcan.2009.05.015>.

[34]

Hansen O, Paarup H, Sørensen P, **Hansen KH**, Werenberg KA. **[Curative radiotherapy of local advanced non-small-cell lung cancer. Eight years of experience from Odense].** Ugeskr Laeger 2005;167:3497–502.